Dr. Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc., which uses artificial intelligence on live cancer cell analytics to predict how a patient will respond to cancer therapy drugs. He received his PhD degree in Bioengineering from Stanford University and a master’s degree in Translational Medicine from the UC Berkeley–UCSF Joint Bioengineering Program. Sungwon is a bioengineer and entrepreneur with 20 years experience in academia and biotech companies, with a focus on the development of novel cancer therapies. He is a strong advocate of functional precision medicine – personalizing a cancer treatment regimen based on each patient’s cancer cells’ functional responses to anti-cancer drugs, beyond cancer genetics.
IVC Journal is a division of Redstone Media Group. Innovation is the key to veterinarians staying competitive and being able to provide their clients with the absolute best care possible. IVC Journal delivers the most up to date and compelling information available by bridging the gap between the traditional worlds of allopathic and integrative veterinary care.